Radboud University Medical Center
- Country
- 🇳🇱Netherlands
- Ownership
- Private
- Established
- 1951-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.radboudumc.nl
Clinical Trials
1.1k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (763 trials with phase data)• Click on a phase to view related trials
Smart Pill for Measuring Gut Health in Colon Inflammation and Colon Cancer
- Conditions
- Colorectal Cancer (CRC)Ulcerative Colitis (UC)
- First Posted Date
- 2025-07-01
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT07046468
- Locations
- 🇳🇱
Radboud university medical center, Nijmegen, Gelderland, Netherlands
The Impact of Artificial Intelligence on Dentists' Decision-Making Process During Caries Detection
- Conditions
- Artificial Intelligence (AI) in DiagnosisArtificial Intelligence Supported Image Reviewing
- First Posted Date
- 2025-06-18
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT07027189
- Locations
- 🇳🇱
Department of Dentistry Radboud Uniersity Medical Center, Nijmegen, Gelderland, Netherlands
Lifestyle Intervention for Symptoms of Depression wIth App Support in General Practice
- Conditions
- Depressive/Anxiety SymptomsDepressive Disorder
- First Posted Date
- 2025-06-15
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 216
- Registration Number
- NCT07022184
- Locations
- 🇳🇱
Radboudumc, Nijmegen, Gelderland, Netherlands
🇳🇱Amsterdam UMC, Amsterdam, Noord-Holland, Netherlands
🇳🇱UMC Groningen, Groningen, Netherlands
TGW211 for Click-Cleavable Imaging in HER2-Positive Cancers.
- Conditions
- HER2 Positive Solid Tumor
- Interventions
- Drug: [111In]In-DOTA-TCO-trastuzumabDrug: Small molecule tetrazine trigger component
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 19
- Registration Number
- NCT07009184
Slow-SPEED: Slowing Parkinson's Early Through Exercise Dosage
- Conditions
- Parkinson DiseaseProdromal StageNeurodegenerative DiseasesBasal Ganglia DiseasesCentral Nervous System DiseasesSynucleinopathiesNervous System DiseasesCerebral DisorderBrain DiseasesParkinsonian Disorders
- First Posted Date
- 2025-05-28
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 600
- Registration Number
- NCT06993142
- Locations
- 🇺🇸
University of Rochester Center for Health and Technology (CHeT), Rochester, New York, United States
🇳🇱Radboud University Medical Center, Nijmegen, Gelderland, Netherlands
- Prev
- 1
- 2
- 3
- 4
- 5
- 190
- Next
News
Two New Tuberculosis Drugs Show Superior Safety Profile Over Linezolid in Phase 2b Trials
Two Phase 2b clinical trials led by LMU University Hospital Munich demonstrated that sutezolid and delpazolid, both oxazolidinone antibiotics, offer safer alternatives to linezolid for tuberculosis treatment with no cases of nerve damage or blood toxicity observed.
Philikos Initiates Phase 1/2 Trial of T-Guard for Diffuse Cutaneous Systemic Sclerosis
Philikos has enrolled the first patient in a Phase 1/2 trial evaluating T-Guard for diffuse cutaneous systemic sclerosis (dcSSc), a severe autoimmune disorder with limited treatment options.
Imec Unveils Revolutionary Miniaturized Ingestible Sensor for Non-Invasive Gut Health Monitoring
Imec has developed a highly miniaturized ingestible sensor measuring just 2.1cm in length and 0.75cm in diameter, three times smaller than existing capsule endoscopies, capable of monitoring gut health for up to a week.
Thiogenesis Launches Phase 2 Trial of TTI-0102 for MELAS, a Rare Mitochondrial Disease
Thiogenesis Therapeutics has dosed the first two patients in its Phase 2 clinical trial of TTI-0102 for MELAS, a rare inherited mitochondrial disease with no approved treatments in the EU or US.
Immunotherapy Shows Promise in Prostate Cancer with MMRd Mutation
Men with prostate cancer and the MMRd mutation experienced significantly extended progression-free survival with dual immunotherapy.
Verily Partners with Dutch Institutions to Launch Large-Scale Parkinson's Disease Study
Google's life sciences division Verily collaborates with Radboud University Medical Center and ParkinsonNet to study disease progression in 650 Parkinson's patients using advanced imaging and wearable technology.